VIBHA T THOMAS
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology CARROLLTON, TX NPI 1801004825
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology TX PFIZER INC. All categories
General Payments — all program years on this page
$5,172.71
- Category: General Payments
- Program years: PY2018–2024
- Record count: 264
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,447.06 across 60 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,447.06 | 60 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $142.44 | 6 |
| Acerta Pharma LLC | $119.90 | 4 |
| Merck Sharp & Dohme Corporation | $113.01 | 5 |
| Gilead Sciences, Inc. | $95.93 | 4 |
| Tempus AI, Inc | $91.91 | 2 |
| Celgene Corporation | $75.82 | 4 |
| Janssen Biotech, Inc. | $75.29 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $71.02 | 3 |
| ABBVIE INC. | $65.20 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $56.56 | 2 |
| Genentech USA, Inc. | $50.39 | 2 |
| Incyte Corporation | $50.18 | 2 |
| Adaptive Biotechnologies Corporation | $47.96 | 2 |
| ADC Therapeutics America, Inc. | $45.94 | 2 |
| Stemline Therapeutics Inc. | $45.75 | 2 |
| ARRAY BIOPHARMA INC | $41.77 | 2 |
| PharmaEssentia USA Corporation | $34.87 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $34.19 | 2 |
| EISAI INC. | $30.67 | 1 |
| GENZYME CORPORATION | $29.82 | 1 |
| Daiichi Sankyo Inc. | $26.65 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $24.89 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $23.49 | 1 |
| Lilly USA, LLC | $21.05 | 1 |
| TAIHO ONCOLOGY, INC. | $17.41 | 1 |
| GlaxoSmithKline, LLC. | $14.95 | 1 |
By program year
Records — PY2024 (60)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.